<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00122226</url>
  </required_header>
  <id_info>
    <org_study_id>protocol 02-72</org_study_id>
    <nct_id>NCT00122226</nct_id>
  </id_info>
  <brief_title>MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)</brief_title>
  <official_title>MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <brief_summary>
    <textblock>
      This is a randomized prospective study into metabolic adverse events during different types&#xD;
      of initial antiretroviral therapy in HIV-1-infected men.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized prospective study into metabolic adverse events during initial&#xD;
      antiretroviral therapy in HIV-1-infected men. The following regimens are compared:&#xD;
      lopinavir-ritonavir + Combivir and lopinavir-ritonavir + nevirapine (nucleoside reverse&#xD;
      transcriptase inhibitor [NRTI]-sparing). Prior to the start of therapy and 3, 12, 24, and 36&#xD;
      months thereafter the distribution of body fat and bone density (bioelectrical impedance&#xD;
      analysis [BIA], computed tomography [CT] and dual energy x-ray absorptiometry [DEXA]), lipid&#xD;
      spectrum, mitochondrial DNA (peripheral blood mononuclear cells [PBMCs] and adipose tissue&#xD;
      biopsies) and vascular measurements are performed. In addition, insulin sensitivity is&#xD;
      measured in a subgroup of sixteen individuals by using a hyperinsulinemic euglycemic clamp&#xD;
      and performing microvascular measurements. The aim of the study is to obtain prospective&#xD;
      insight into the occurrence of various aspects of metabolic adverse events on the one hand&#xD;
      and to compare an NRTI-containing therapy with an NRTI-sparing therapy on the other hand. The&#xD;
      hypothesis is that in the NRTI-sparing arm, less metabolic and vascular changes are observed&#xD;
      than in the NRTI containing regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2003</start_date>
  <completion_date>July 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin resistance (3, 12, 24, 36 months)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>microvascular function (3, 12, 24, 36 months)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>lipid profile (3, 12, 24, 36 months)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>body composition (3, 12, 24, 36 months)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>macrovascular function (12, 24, 36 months)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>mitochondrial DNA in PBMC and fatty tissue (12, 24, 36 months)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gene expression, markers of mitochondrial toxicity, inflammation, apoptosis, fat cell differentiation in fatty tissue (12, 24, 36 months)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone mineral density (12, 24, 36 months)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>natural killer cells (3, 12, 24 months)</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>HIV Infections</condition>
  <condition>HIV-Associated Lipodystrophy Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir + zidovudine + lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir + nevirapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Age between 18 and 70 years.&#xD;
&#xD;
          -  No prior use of antiretroviral therapy&#xD;
&#xD;
          -  Indication for antiretroviral treatment according to common standards&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female sex&#xD;
&#xD;
          -  Body mass index (kg/m2) &gt; 35.&#xD;
&#xD;
          -  Known history of diabetes mellitus or hyperlipidemia&#xD;
&#xD;
          -  Use of coenzyme A reductase inhibitor or fibric acid derivative in the last 6 weeks&#xD;
             before inclusion&#xD;
&#xD;
          -  Use of the following medication: systemic corticosteroids, thiazide diuretics,&#xD;
             calcium-entry blockers, angiotensin-converting inhibitors, nitrates&#xD;
&#xD;
          -  Use of nandrolone or testosterone&#xD;
&#xD;
          -  Any disorder or condition which can be expected to lead to lessened compliance with&#xD;
             the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. A. Danner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Free University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. Reiss, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center, National AIDS Therapy Evaluation Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Jan van Goyen</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis, location Oosterpark</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis, location Prinsengracht</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slotervaart ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VUMC Free University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Leyenburg</name>
      <address>
        <city>den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis, location Elisabeth</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Universitair Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2005</verification_date>
  <study_first_submitted>July 14, 2005</study_first_submitted>
  <study_first_submitted_qc>July 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <last_update_submitted>April 24, 2006</last_update_submitted>
  <last_update_submitted_qc>April 24, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2006</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>HIV-associated lipodystrophy syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

